International Journal of Medical Sciences

Impact factor
2.399

20 October 2017

ISSN 1449-1907 News feeds of published articles

My Manuscript | My Account

Journal of Genomics now in PubMed/PubMed Central. Submit manuscript...

Journal of Biomedicinenew

Theranostics

Journal of Cancer

Oncomedicine

International Journal of Biological Sciences

Journal of Genomics

Journal of Bone and Joint Infection (JBJI)

Nanotheranostics

PubMed Central Indexed in Journal Impact Factor

Int J Med Sci 2014; 11(3):276-281. doi:10.7150/ijms.7627

Research Paper

Comparison of the Inhibitory Effect of Gonadotropin Releasing Hormone (GnRH) Agonist, Selective Estrogen Receptor Modulator (SERM), Antiprogesterone on Myoma Cell Proliferation In Vitro

Youn-Jee Chung1, Boah Chae1, Se-Hyun Kwak1, Jae-Yen Song1, Ah-Won Lee2, Hyun-Hee Jo1, Young-Ok Lew1, Jang-Heub Kim1, Mee-Ran Kim1✉

1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea
2. Department of Hospital Pathology, The Catholic University of Korea, Republic of Korea

Abstract

Uterine myomas are the most common gynecologic tumor in women of reproductive age. Treatment options of uterine myomas consist of surgical, medical and interventional therapy such as uterine artery embolization or myolysis. Given that it is the most common type of tumor in women of reproductive age, the treatment of uterine myomas must prioritize uterine conservation. There are several drugs for medical treatment of uterine myoma such as gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM) and antiprogesterone. The objective of this study was to compare the effect of GnRH agonist, SERM, and antiprogesterone in the treatment of uterine myomas in vitro. The effect of drugs was evaluated through the cell viability assay in cultured leiomyoma cells, western blot analysis of proliferating cell nuclear antigen (PCNA), and BCL-2 protein expression. As a result, mifepristone single-treated group represents the most significant reduction in myoma cell viability and proliferation. When pretreated with leuprolide acetate, raloxifene shows more significant reduction in myoma cell viability and proliferation than mifepristone. This study suggests one of the possible mechanisms how medications act on uterine myoma, especially at the molecular level.

Keywords: Leiomyoma, Drug therapy, Gonadotropin-releasing hormone agonist, Raloxifene, Mifepristone

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Chung YJ, Chae B, Kwak SH, Song JY, Lee AW, Jo HH, Lew YO, Kim JH, Kim MR. Comparison of the Inhibitory Effect of Gonadotropin Releasing Hormone (GnRH) Agonist, Selective Estrogen Receptor Modulator (SERM), Antiprogesterone on Myoma Cell Proliferation In Vitro. Int J Med Sci 2014; 11(3):276-281. doi:10.7150/ijms.7627. Available from http://www.medsci.org/v11p0276.htm